Showing 1021-1030 of 1688 results for "".
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchange, Raises $50Mhttps://modernaesthetics.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange-raises-50m/2473109/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- National Emsculpt Week is Cominghttps://modernaesthetics.com/news/national-emsculpt-week-is-coming/2473104/BTL Aesthetics is bringing back National Emsculpt Week. This holiday was added to the official National Day
- Cynosure Introduces New Fusion Tip for Potenza RF Microneedling System for Enhanced Topical Penetrationhttps://modernaesthetics.com/news/cynosure-introduces-new-fusion-tip-for-potenza-rf-microneedling-system-for-enhanced-topical-penetration/2473094/Cynosure launched a one-of-a-kind Fusion Tip, the newest addition to its Potenza radiofrequency (RF) microneedling system. With its dual-air chamber design, the Fusion Tip captures and releases air towards the skin with each pulse, enhancing the penetration of topicals into the skin by 67 p
- SuperVision180 Launches with New Approach to Aesthetic Educationhttps://modernaesthetics.com/news/supervision180-launches-with-new-approach-to-aesthetic-education/2473089/Offering courses in more than a dozen aesthetic topics with more on the way, SuperVision180 is now offering education and CME credits in the medical aesthetics space. The platform features live procedural webinars, online courses, and hands-on classes. “This is not Zoom,&rdq
- Sonrei Expands Offerings with Three New Sunscreenshttps://modernaesthetics.com/news/sonrei-expands-offerings-with-three-new-sunscreens/2473088/Sonrei has expanded its product line with three new offerings: Sonrei Clearly Zinq Tinted Mineral Gel Sunscreen SPF 45,
- Phase 3 Data: Endo’s Qwo Smooths Cellulite on the Buttockshttps://modernaesthetics.com/news/phase-3-data-endos-qwo-smooths-cellulite-on-the-buttocks/2473083/Endo’s Qwo provides a clinically meaningful improvement in the appearance of moderate to severe cellulite in the buttocks of adult women, when compared to placebo, according to Phase 3 data. "The data, from the largest cellulite studies ever conducted, provides further eviden
- It's A Deal: Eirion Therapeutics, Shanghai Haohai Biological Technology Close $40M Series A Investment and Licensing Dealhttps://modernaesthetics.com/news/its-a-deal-eirion-therapeutics-inc-shanghai-haohai-biological-technology-closes-40m-series-a-investment-and-licensing-deal/2473070/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- Introducing the Cutaneous Procedures Adverse Events Reporting (CAPER) Systemhttps://modernaesthetics.com/news/introducing-the-cutaneous-procedures-adverse-events-reporting-caper-system/2473065/The American Society for Dermatologic Surgery Association (ASDSA) and the Northwestern University Department of Dermatology are launching the Cutaneous Procedures Adverse Events Reporting (CAPER) system. This voluntary reporting system gathers patients’ adverse events (AEs) encoun
- It’s Settled: AbbVie and Evolus Come to Agreementhttps://modernaesthetics.com/news/its-settled-abbvie-and-evolus-come-to-agreement/2473064/AbbVie, Evolus, and Medytox have agreed to new settlement agreements to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus
- Evolus’ Jeuveau Can Stay on U.S. Market For Nowhttps://modernaesthetics.com/news/evolus-jeuveau-gets-stay-of-execution/2473061/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to